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ABSTRACT
THE EFFECTS OF 1,25-DIHYDROXYVITAMIN D3 , DOCOSAHEXAENOIC ACID
AND 5-FLUOROURACIL ON HUMAN BREAST CANCER CELLS
by
Liv Astri Engelsen
May 2012
It is well documented that vitamin D and DHA have antiproliferative effects on a

variety of human cancers, including breast cancer. Studies have shown that a combination
approach to cancer treatment is more effective than any one treatment administered
alone. In this study, human mammary epithelial cells from the MCF-7 cell line were
treated with 25 µM DHA, 1 µM calcitriol, and 15 µM 5-Fluorourocil alone and in
multiple combinations for 72 hours. Both DHA and 5-Fluorouracil slowed growth
significantly (p < 0.05). In contrast, vitamin D did not inhibit cell growth at 1 µM. The
combination of vitamin D and DHA inhibited cell growth slightly more than DHA alone.
Interestingly, DHA was just as effective as 5-Fluorouracil at inhibiting cell growth. These
results suggest that DHA may be just as efficacious as 5-Fluorouracil in slowing breast
cancer progression and therefore may suggest a dietary approach to breast cancer
treatment with low toxicity.
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CHAPTER I
INTRODUCTION AND LITERATURE REVIEW
Introduction
Cancer broadly describes a large number of disease types all characterized by
uncontrolled cell division and regulation. Currently one in four deaths (approximately
1500 per day) occur as a result of cancer, making it the second cause of death in the
United States (Jemal et al., 2010). The process of cancer development, carcinogenesis,
occurs in three steps - initiation, promotion and progression. During the initiation stage,
the DNA within a cell is altered. This can be a result of an environmental insult (exposure
to a carcinogen) which can result in the formation of free radicals that can cause damage
to many parts of the cell, including the DNA. In the promotion stage, the damaged cells
begin to divide at an uncontrollable rate resulting in tumor formation. The tumor may
then either remain benign and contained, or it may enter the progression stage in which
metastasis occurs and the cells infect other healthy tissues of the body.
Under normal conditions, there are several mechanisms in place that keep cell
division tightly regulated. Some of these controls are genetic or hormonal, often
involving growth factors such as interleukins and cytokines, or chemical signals from
other cells. Two types of genetic mechanisms involve genes called oncogenes and tumorsuppressor genes. While oncogenes turn on the signal for cell growth, suppressor genes
turn it off (Nelms et al., 2007). An important protein involved in the normal cell cycle
process is p53, which is a tumor suppressor gene that prevents cells with damaged DNA
1
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from dividing until the DNA is repaired. Known as the "guardian" of the genome, this
protein exerts its effects by upregulating the gene p21 which inhibits cyclin-dependent
kinase (CDK). Once the cell cycle is disrupted by these proteins, DNA can then be
repaired or the cell can be stimulated to undergo apoptosis (Ford et al., 2004).
Unfortunately, p53 is suppressed in many tumors and completely inactivated in about
half of all cancer cases (Levine, 1997). In fact, p53 mutations occur in breast cancer cases
only about 30% of the time, which is much lower than some other cancer types. In many
of the breast cancer cases in which a mutation does not occur, p53 is removed from the
nucleus and compartmentalized in the cytoplasm of the cell, known as nuclear exclusion,
where it is completely inactivated (Moll et al., 1992).
Apoptosis, or programmed cell death, is a process that normal cells undergo to
prevent damaged cells from reproducing and is vital to eukaryotic life. The main groups
of molecules that play a major role in the process of apoptosis include caspases, Bcl-2
proteins, members of the tumor necrosis factor receptor (TNF-R) superfamily, and p53
(Pardee, 2004). Apoptosis is carried out by caspases and nucleases which are activated by
Bax (pro-apoptosis) and deactivated by Bcl-2 (pro-survival) proteins (Pardee, 2004).
Caspases are proteases that cleave a number of proteins, which can either activate or
inactivate them. These cysteine proteases exist as zymogens within the cell and must be
activated under apoptotic conditions (Wang & El-Deiry, 2004). Out of the 11 caspases in
humans, 7 of them are closely involved in regulating apoptosis (Reed & Green, 2011 ).
Initiator caspases (2, 8, 9, and 10) activate effector caspases (3, 6, and 7) which induce a
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cascade of activation. Once activated, effector caspases inactivate a variety of cellular
proteins, ultimately killing the cell (Wang & El-Deiry, 2004).
Carcinogenesis occurs when many of these anticancer regulatory mechanisms are
breached simultaneously. Researchers have identified six key physiological mutations
within the cell that are required for cancer development and tumorigenesis (see Table 1).
These mutations are similar in most, if not all cancer types and can arise at various times
during this multi-step process (Hanahan & Weinberg, 2000).
. I to tumongenes1s.
. (H ana han & W.
T a ble 1: Th e SIX
. ha II mark capabT.
1 1t1es essentia
em b erg, 2000)

Component

Acquired Capability

Example of Mechanism

3

Self-sufficiency in growth
signals
Insensitivity to antigrowth
signals
Evading apoptosis

4

Limitless replicative potential

Produce insulin-like growth factor
survival factors
Turn on telomerase

5

Sustained angiogenesis

Produce VEGF inducer

6

Tissue invasion and metastasis

Inactivate E-cadherin

1

2

Activate H-Ras oncogene
Lose retinoblastoma suppressor

Breast Cancer

Breast cancer is the most frequently diagnosed type of cancer in women and is
among the most lethal. An estimated 207,090 women were diagnosed with breast cancer
in 2010 in the United States, which accounts for 28% of all new cancer cases in this
group. Death rates from breast cancer have been steadily declining in North America
since the early 1990s largely due to early detection and current treatment efforts.
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However, breast cancer remains the leading cause of cancer-related death among women
between the ages of20 and 59 (Jemal et al., 2011; Jemal et al., 2010).
Over half of all breast cancer cases are in industrialized countries, and rates are
nearly five times higher in Western countries than in developing countries and Japan, an
observation supporting the role of environmental factors in carcinogenesis. Migrant
studies have further supported that these factors play a major role in the onset of breast
cancer since a woman's risk for developing breast cancer typically increases when she
moves from a developing country (or from Japan) to the US or Canada (AICR/WCRF).
Although epidemiological studies show correlations between cancer rates and certain
dietary factors, it is challenging to label a single food or drink as a carcinogen. Relating a
specific nutrient deficiency to carcinogenesis is equally difficult due to the large number
of environmental factors that may play a contributing role (Nelms et al., 2007). For
example, an earlier age of menarche and post-menopausal obesity are more common in
Western cultures, both of which increase estrogen levels, a hormone that has been linked
to the development of breast cancer (AICR/WCRF).
Characterized by estrogen-dependent growth, breast cancer progression is most
often dependent on proliferation of breast cancer cells that occurs through the estrogen
receptors (ER) of the cell, which are classified as steroid receptors in the nuclear receptor
superfamily (Mangelsdorf et al., 1995). While the role of ER~ receptors in breast cancer
is unclear, the estrogen receptor ERa is an important marker for breast cancer diagnosis
and prognosis. About one third of all breast cancer cases are ERa negative which are
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known to have a poorer prognosis than those that are ERa positive (Osborne, 1998;
Jensen, 2004).
A tumor suppressor gene known as breast cancer gene 1 (BRCA 1) plays an
important role in mammary carcinogenesis. Mutations in the BRCAl and BRCA2 genes
have been linked to a poor prognosis for recovery in breast cancer cases, and complete
loss of BRCAl results in DNA replication errors that can facilitate other malignancies
(Madjd et al., 2011). Genetic inheritance of a mutant BRCAl or BRCA2 gene correlates
with an estimated lifetime risk for breast cancer of roughly 78% (Brose et al., 2002).
Once a breast tumor metastasizes, quality of life and duration of survival count on
the patient's sensitivity to the chemotherapy treatments. The efficacies of such treatments
are typically dose-dependent, which is often limited due to the high level of side effects
from radiation and chemotherapy drugs. Any supplemental and non-toxic treatment with
the potential to increase tumor sensitivity to anti-cancer drugs could contribute to a
favorable prognosis and treatment outcome (Bougnoux et al., 2009).
Litrerature Review

Vitamin D
Though technically a prohormone, vitamin D is well known for its important role
in bone formation and calcium homeostasis (DeLuca, 2004). Although it can be absorbed
through the skin from UVB radiation and then hydroxylated to the metabolically active
form in the liver and kidneys, vitamin D deficiency is still prevalent in the United States
(Stiff & Miller, 2009). This is partially due to the fact that between October and March,
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the amount of ultraviolet radiation from the sun is inadequate in any location above 35°
latitude, which includes about two-thirds of the U.S. It is logical that most adults in the
U.S., especially those who live in the northern regions, have insufficient levels (21 ng/mL
to 29 ng/mL) of serum vitamin D (Stiff & Miller, 2009). Although vitamin D can be
consumed in the diet, it is only found naturally in seafood, mushrooms, and egg yolks, so
nutritional supplementation is generally recommended (Moyad, 2009).
The Institute of Medicine (IOM) updated the recommended dietary allowances
(RDA) for vitamin Din November of 2010, but recommended levels fall short of the
amounts required for optimal health, according to many professionals (see Table 2). This
is partially due to the fact that the IOM made the recommendations based on the
appropriate levels of vitamin D necessary for bone health since evidence for the role of
vitamin D in the prevention of cancer, cardiovascular disease, diabetes, and other
autoimmune disorders is inconclusive (Ross et al., 2011 ). The RDA for vitamin D for
individuals between the ages of 1 and 70 is currently 600 IU/day, which corresponds with
a serum level of 20 ng/ml (50 nmol/L). Many experts believe a more appropriate
recommendation for vitamin D would be in the range of 1000-2000 IU/day, especially in
locations north of the equator. It is estimated that the body's daily requirement of vitamin
D is around 3000-5000 IU/day (Heaney et al., 2003).
Table 2: Assessment of serum 25(0H)D levels for health (Holick, 2009)

Deficient

Insufficient

Optimal

Toxic

<20 ng/ml

21-29 ng/ml

>30 ng/ml

> 150-200 ng/ml
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Vitamin D functions through the vitamin D receptor (VDR) of human cells. Once
believed to be present only in cells involved in bone formation, VDRs are now known to
be present in nearly every nucleated cell in the human body, including mammary cells.
Along with their ligands, VDRs control proliferation, apoptosis and differentiation at
different stages in cellular development (Welsh, 2007). VDRs belong to the nuclear
receptor superfamily and provide a link between signaling molecules on the cell surface
and gene transcription factors within the cell. When calcitriol, the active form of vitamin
D, binds to the VDR, it forms a dimer complex with another receptor known as retinoid
X receptor (RXR). This complex then binds to vitamin D response elements (VDREs)
which are specific DNA sequences of target genes, allowing transcription to occur (Ma,
et al., 201 O; Colston & Hansen, 2001 ). Through this regulation of gene expression,
vitamin D is able to maintain the differentiated phenotype of mammary cells and allows it
to possibly play a role in the prevention and treatment of breast cancer (Welsh, 2007).
The relationship between vitamin D status and disease onset and prognosis has
been a recent area of interest in all levels of research. Many studies have suggested that
there is a negative relationship between vitamin D status and breast cancer risk (Abbas et
al., 2008; Crew et al., 2009; Rejnmark et al., 2009) although other studies have failed to
establish this relationship (Chlebowski et al., 2008; Freedman et al., 2008; McCullough et
al., 2009). A case control study comparing 701 cancer cases to 724 matched controls
revealed that women with high levels of serum 1,25(0H)D, and possibly 1,25(0H)2 D,
were at a low risk of developing breast cancer, and this was especially evident in women
over 60 years of age (Bertone-Johnson et al., 2005). One study looking at data from
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NHANES III observed no relationship between vitamin D status and cancer death, but
did find that individuals with vitamin D levels of <17.8 ng/ml had a 26% higher risk of
all-cause mortality (Melamed et al., 2008). Other studies have indicated that the lowest
number of cancer mortalities occurred in cancer cases that were diagnosed during the
summer and fall, when serum vitamin D 3 levels are typically the highest (Robsahm et al.,
2004; Lim et al., 2006). A randomized placebo controlled trial in 2007 gave 1179 postmenopausal women either calcium supplementation ( 1400-1500 mg), calcium plus
vitamin D (1100 IU), or a placebo each day and followed them for 4 years. They
discovered that the rate of cancer diagnosis was significantly lower in the calcium plus
vitamin D group than the calcium or control group. The findings suggest that increasing
dietary intake of calcium and vitamin D decreases cancer risk in this population (Lappe et
al., 2007).
Research has consistently found that vitamin D exhibits antitumor effects on
breast cancer cells in vitro, mainly by inducing apoptosis, but also through proliferation
inhibition (Deeb et al., 2007). One study showed that apoptosis is induced within 48
hours in MCF-7 cells treated with 100 nM of l,25(0H)iD 3 (Welsh, 1994). Lower
concentrations appear to be effective at reducing cell viability as well and MCF-7 cells
exhibited growth inhibition after 96 hours of treatment at concentrations ranging from 10
to 100 nM/L 1,25(0H)2 D 3 (Kemmis et al., 2006). A similar study compared the effects of
1,25(0H)2 D 3 to a low calcemic vitamin D analog on MCF-7 cells. They discovered that
both compounds reduced the number of viable cells in a dose and time dependent
manner, and that the vitamin D analog was 50 times more effective than 1,25(0H)2 D 3
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(Simboli-Campbell et al., 1997). Researchers in Denmark discovered that vitamin D and
their analogues both slowed the growth and induced apoptosis of human MCF-7 breast
cancer cells. Interestingly, these effects occurred independently of caspase activation and
p53, while overexpression of Bcl-2 protected the cells from apoptosis (Mathiasen et al.,
1999). In another study, MCF-7 cells were pre-treated with the polyphenols resveratrol
(from red wine) and genistein (from soy) to mimic the effects of estrogen and increase
VDR expression prior to treatment with 100 nM calcitriol. The researchers found that
both phytoestrogens increased cellular sensitivity to vitamin D, but more so with
reservatrol (Wietzke & Welsh, 2003).
The MCF-7 cell line is characterized by a phenotype that is estrogen-receptor
(ER) positive and therefore may be more responsive to treatment. Comparison of the
effects of l ,25(0H) 2 D 3 on ER+ cells (MCF-7) and ER- cells (MDA MB 231) resulted in
antiproliferative effects that occurred by different genetic mechanisms, but these effects
were much stronger in the MCF-7 cells. The mechanisms by which apoptosis was
induced in the MCF-7 cell line included the upregulation ofp53, p21-activated kinase
(PAC-1), and caspases (Swami et al., 2003). Researchers discovered that vitamin D
downregulates ER levels in the MCF-7 cell line which could play an important role in its
antiproliferative actions (Swami et al., 2000).
Due to the fact that high levels of vitamin D are required to obtain anti-cancer
effects in vitro, few clinical trials have used quantities large enough to produce similar
results out of fear of inducing hypercalcemia. Daily oral dosing of 0.5 µg to 1.5 µg
induced hypercalcemia and did not improve patient prognosis in a sample of 14 subjects
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with advanced prostate cancer (Osborn et al., 1995). However, several studies have
established that adequate doses of calcitriol can in fact be safely administered if it is done

.

in an intermittent manner (Ma et al., 2010). In one study, oral calcitriol was given to 15
patients with refractory malignancies on a weekly basis for 20 cycles of therapy. Weekly
dosing in this manner up to 2. 8 µg/kg per week was effective and resulted in minimal
toxicity. A plateau was observed in calcitriol concentrations at about 0.48 µg/kg and peak
serum calcitriol concentrations ranged from 3.7 to 6.0 nM (Beer et al., 2001).
DHA

Docosahexaenoic Acid (DHA) is an omega-3 polyunsaturated fatty acid (PUF A)
that is not only vital to proper visual and neurological development, but has been
implicated in the treatment and prevention of many diseases, including cancer (Head,
2009). Both omega-3 and omega-6 fatty acids are considered to be essential fatty acids
(EF As) and must be consumed in the diet. These fatty acids are not interchangeable in the
body because humans lack the enzyme omega-3 desaturase, which is necessary to convert

n-6 to n-3 (Simopoulos, 2006). DHA is one of the three major n-3 FAs, the other two
being eicosapentaenoic acid (EPA) and a-linolenic acid (ALA) (Hardman, 2002). The
best dietary source of DHA and EPA is fatty cold water fish such as wild salmon (see
Table 3). Fish oil supplements usually contain both EPA (usually the dominant fatty acid)
and DHA which are extracted from krill and microalgae (Head, 2009). DHA and EPA
can also be synthesized in the body from ALA, the less bioavailable plant n-3 fatty acid.
However, studies suggest the capacity to convert ALA to EPA and DHA in humans is
very low. It is estimated that only about 5-10% of ALA is converted to EPA and about 2-
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5% is converted to DHA in healthy adults. In addition, the conversion rate is lowered by
40-50% when combined with a diet that is relatively high in n-6 F As (Gerster, 1998). The
most abundant n-3 fatty acid in most Western diets, ALA is found in certain vegetable
oils, green leafy vegetables, walnuts, flax and chia seeds (Hardman, 2002; Leitzmann et
al., 2004).
Table 3: DHA, EPA, and ALA content ofomega-3-rich foods. I tbsp oil= 13.6 g., 1 tbsp seeds/nuts=
28.35 g. (USDA nutrient database release 24).

Food Source
(per serving)
Cod

DHA+EPA
(ml!)
134

Food Source
(per tablespoon)
Pumpkin seeds

ALA
(mg)
51

Catfish

151

Soybean oil

1,231

Clams

241

Canola oil

1,302

Shrimp

267

Walnut oil

1,414

Flounder

426

Flaxseeds

2,350

Pollock

460

Walnuts, English

2,574

Tuna, canned

733

Chia seeds

5,055

Salmon

1825

Flaxseed oil

7,249

It appears that the type, rather than the amount, of dietary fat consumed may be

more important in the pathogenesis of breast cancer (Grammatikos et al., 1994). The ratio
of dietary n-6 to n-3 is especially important because both fatty acids compete with each
other for an enzymatic substrate needed to produce prostaglandins (Bagga et al., 2002;
Culp et al., 1979). The human population evolved on a ratio of dietary n-6 to n-3 fatty
acids close to 1, but that ratio is now about 15/1 to 16. 7/1 in a typical Western diet
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(Simopoulos, 2001). Omega-3 fatty acids exhibit anti-inflammatory effects by
suppressing inflammatory cytokines such as interleukin 1~ (IL-1 ~), interleukin 6 (IL-6)
and tumor necrosis factor (TNFa). N-6 fatty acids, on the other hand, are proinflammatory. This observation is one reason why a lower dietary ratio of n-6 to n-3 is
beneficial to people suffering from or at risk for diseases characterized by inflammation
(Simopoulos, 2006). Some of the diseases that have been linked to diets rich in n-6 fatty
acids and low in n-3 fatty acids include cardiovascular disease, hypertension, renal
disease, diabetes, arthritis, ulcerative colitis, Crohn's disease, and cancer (Simopoulos,
1999).
Epidemiological studies have revealed a negative correlation between the intake
of n-3 fatty acids and cancer risk. Omega 3 fatty acids have clear anticarcinogenic
properties in animal models and in vitro, while omega 6 fatty acids tend to have the
opposite effect by increasing cancer risk (Grammatikos et al., 1994; Fay et al., 1997;
Hardman, 2002; Connolly et al., 1999). Not surprisingly, epidemiologic research has
revealed lower incidences of breast cancer in locations where fish makes up a larger part
of the diet, and higher incidences where vegetable oils are consumed in greater quantities,
such as the U.S. (Grammatikos et al., 1994). As the diets of Japanese women have
become more westernized and lower in n-3 fatty acids, death rates from breast cancer in
this population have been on the rise (Lands et al., 1990).
Studies have noted a negative correlation associated with risk for other types of
cancers as well, including prostate cancer. A 12-year follow-up study of nearly 50,000
men revealed that the consumption of fish more than three times per week was associated
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with a reduced risk of prostate cancer. In addition, it was noted that for every 0.5 g
increase of dietary marine fatty acids per day, overall risk of metastatic cancer decreased
by 24% (Augustsson et al., 2003).
Assessment of the dietary intakes of 3081 breast cancer survivors participating in
the Women's Healthy Eating and Living (WHEL) study revealed that women with the
highest intakes of EPA and DHA from food (> 73 mg/day) had a 25% reduction in
further breast cancer events as compared with the group with the lowest intakes. Higher
intakes of dietary EPA and DHA also correlated with a reduced risk of all-cause mortality
in a dose-dependent manner (Patterson et al.,2011 ). The results of another study
comparing the dietary patterns of 358 breast cancer patients and 360 controls with no
history of cancer found that high intakes of fatty fish were associated with reduced breast
cancer risk (Kim et al., 2009).
The analysis of breast adipose tissue is an accurate and practical estimate of
dietary fat intake. A case-control study carried out in France examined the fatty acid
composition of breast adipose tissue from 329 patients with either breast cancer or benign
breast disease and determined that n-3 fatty acid levels were inversely associated with
breast cancer risk (Maillard et al., 2002). Another study comparing 73 breast cancer
patients to 74 controls found that the levels of n-6 PUFA in the breast adipose tissue was
significantly higher in the breast cancer patients as compared with the controls (Bagga et
al., 2002).
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Research on animal models has confirmed the protective effects of DHA as it
relates to carcinogenesis, as well as its effect on breast tumor growth and metastasis. One
study revealed that mice fed a diet rich in ALA from flaxseed displayed a decreased
growth rate of mammary tumors and an inhibition of tumor metastasis (Chen et al.,
2002). A novel study using a combined treatment of fish oil (Maxepa) and 1,25dihydroxyvitamin D3 on rats with DMBA-induced breast cancer revealed a significant
decrease in the amount and incidence of mammary tumors as compared to effects of the
compounds administered alone. Researchers found that the chemotherapeutic effects of
daily oral doses of fish oil and vitamin D3 occurred as a result of reduced cell
proliferation and decreased levels of inducible nitric oxide synthase (iNOS) (Chatterjee
et al., 2010).
In vitro studies have revealed that omega-3 fatty acids in the form of DHA

significantly increase the rate of apoptosis and differentiation in human MCF-7 breast
cancer cells and inhibit their growth (Kang et al., 2010). One study evaluated some of the
mechanisms behind DHA-induced apoptosis in this cell line and found that it occurs via
reactive oxygen species (ROS) formation and activation of caspase 8 (Kang et al., 2010).
A similar study using MCF-7 cells confirmed this effect and found that as apoptosis was
induced, so was the expression of procaspase-8 and bcl-2 (Corsetto et al., 2011). While
DHA has been shown to reduce the growth ofMCF-7 breast cancer cells by up to 50% in
a dose-dependent manner (6-30 µM), DHA at levels below 24 µM had no effect on
noncancerous human mammary cell lines (Grammatikos et al., 1994).
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Although the mechanisms behind the chemotherapeutic effects of DHA are not
well defined, evidence suggests that one reason for the opposing effects essential fatty
acids have on tumor expression is due to prostaglandin E2 (an eicosanoid), which is
known to enhance tumor growth. While prostaglandin E2 originates from n-6 fatty acids,
n-3 fatty acids inhibit its production (Norman et al., 2003). Most of the various proposed

mechanisms for the anticancer effects of DHA including the reduction of cell
proliferation and neoplastic transformation as well as enhanced apoptosis and
antiangiogenicity are either directly or indirectly related to their inhibition of eicosanoid
production from n-6 fatty acids (Kang et al., 2010). A study using the breast cancer cell
line MDA-MB-231 discovered that cell growth was stimulated by n-6 and n-9 PUF As,
and inhibited by n-3 PUF As, particularly DHA and to a lesser extent, EPA (Rose &
Connolly, 1990).
5-Fluorouracil

5-Fluorouracil is an antimetabolite that induces apoptosis by targeting the enzyme
thymidylate synthase (TS) which disrupts DNA synthesis within the cell. It has been
shown to work synergistically with DHA to slow cell growth in colon cancer cells more
effectively than either compound administered alone, and was effective in low-dose
combinations (Calviello et al., 2005). A study carried out on 56 breast cancer patients
revealed an association between the levels of DHA in mammary adipose tissue and the
patient's response to chemotherapy treatment. After a combined treatment with
vindesine, cyclophosphamide, and 5-Fluorouracil, it was reported that the patients with
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the largest decrease in tumor size following treatment were the ones with elevated levels
of DHA (Bougnoux et al., 1999).
The combined therapeutic effect of vitamin D and 5-Fluorouracil has also been
found to produce some promising results in vitro. A study published in 2010 revealed that
vitamin D enhanced the susceptibility of human colon cancer cells to the effects of 5Fluorouracil by activating the calcium-sensing receptor which decreases the expression of
survivin and thymidylate synthase within the cell. Since 5-Fluorouracil works by
targeting thymidylate synthase, a lower expression of TS increased the efficacy of the
drug (Liu et al., 2010). Another study using human MCF-7 cells sought to determine
whether pretreating the cells with vitamin D and/or all-trans-retinoic acid (ATRA) would
increase the efficacy of the cytotoxic drugs paclitaxel (Taxol) and Adriamycin. The
researchers concluded that vitamin D and ATRA both increased cellular sensitivity to the
chemotherapy drugs, and this occurred when administered both in combination and
individually (Wang et al., 2000). In another study, researchers pretreated MCF-7 cells
with 10 nM 1,25(0H)2 D 3 before exposing them to doxorubicin and observed a
synergistic effect. Interestingly, in this study 1,25(0H)2 D 3 exhibited no effect on cell
number and viability on its own (Ravid et al., 1999).
In summary, vitamin D and DHA appear to have chemotherapeutic properties that
are evident both in vitro and in vivo. Few studies have evaluated the combined effects of
these compounds, which was a primary objective of ours. The ability of vitamin D and/or
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DHA to exhibit anticancer effects in vitro suggests the possibility of a promising clinical
application for breast cancer patients.
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Abstract
It is well documented that vitamin D and DHA have antiproliferative effects on a

variety of human cancers, including breast cancer. Studies have shown that a combination
approach to cancer treatment is more effective than any one treatment administered
alone. The purpose of our research was to determine whether the combination of vitamin
D and DHA would demonstrate increased growth inhibition in human MCF-7 breast
cancer cells. We also sought to determine whether these compounds would increase
cellular sensitivity to the antimetabolite chemotherapy drug 5-Fluorourocil, which is
commonly used in the treatment of breast cancer. The ability of either vitamin D or DHA
to enhance the effects of a chemotherapy agent could translate to a decreased drug dosage
requirement and/or a reduction in treatment time for the patient. This would be of benefit
due to the undesirable side effects patients typically experience from cytotoxic drugs. In
this study, human mammary epithelial cells from the MCF-7 cell line were treated with
25 µM DHA, 1 µM calcitriol, and 15 µM 5-Fluorourocil alone and in multiple
combinations for 72 hours. Both DHA and 5-Fluorouracil slowed growth significantly (p
< 0.05). In contrast, vitamin D did not inhibit cell growth at 1 µM. The combination of
vitamin D and DHA inhibited cell growth slightly more than DHA alone. Interestingly,
DHA was just as effective as 5-Fluorouracil at inhibiting cell growth. These results
suggest that DHA may be just as efficacious as 5-Fluorouracil in slowing breast cancer
progression and therefore may suggest a dietary approach to breast cancer treatment with
low toxicity.

27
Introduction
Although breast cancer rates have been declining over the past twenty years due
to early detection and treatment efforts, it still remains the leading cause of cancer death
among women (Jemal et al., 2010). Established risks for developing breast cancer include
obesity, reproductive factors, alcohol consumption, physical inactivity, exogenous
hormones and possibly diet (Parkin et al., 2002). It has been estimated that nutrition
contributes to carcinogenesis in about one-third of the cancers in developed countries,
making dietary factors one of the top preventable causes of cancer (Peto, 2001 ). Recent
estimates further support this relationship and suggest that nutrition and lifestyle factors
may contribute to onset in nearly 80% of prostate and breast cancer cases (Go et al.,
2001).
The relationship between vitamin D status and disease onset and prognosis has
been a recent area of interest in all levels of research. A positive association between
vitamin D status and reduced breast cancer risk has been noted (Abbas et al., 2008; Crew
et al., 2009; Rejnmark et al., 2009). However, some studies failed to establish this
relationship (Chlebowski et al., 2008; Freedman et al., 2008; McCullough et al., 2009).
One study evaluating data from NHANES III observed no relationship between vitamin
D status and cancer death, but did find that individuals with vitamin D levels of <17.8
ng/ml had a 26% higher risk of all-cause mortality (Melamed et al., 2008). Other studies
have indicated that the lowest number of cancer mortalities occurred in cancer cases that
were diagnosed during the summer and fall, when serum vitamin D3 levels are typically
the highest (Robsahm et al., 2004; Lim et al., 2006).

28
Omega 3 fatty acids also have clear anticarcinogenic properties in animal models
and in vitro, while omega 6 fatty acids tend to have the opposite effect and can increase
cancer risk (Grammatikos et al., 1994; Fay et al., 1997; Hardman, 2002). Since much of
the essential fatty acids consumed in the diet get incorporated directly into cell
membranes, they have a significant impact on cellular control and regulation. These fatty
acids are not interchangeable, and by competing with each other for the substrate
necessary to produce prostaglandins they promote contrasting effects on inflammation in
the body. Therefore, the ratio of essential fatty acids consumed in the diet may be a key
in the prevention of cancer. Not surprisingly, epidemiologic research has revealed lower
incidences of breast cancer in locations where fish (rich sources of n-3 fatty acids)
comprise a larger part of the diet, and higher incidences where vegetable oils (rich
sources of n-6 fatty acids) are consumed in greater quantities, such as the U.S.
(Grammatikos et al., 1994).
Studies have revealed that both vitamin D and omega 3 fatty acids in the form of
DHA significantly increase the rate of apoptosis in human MCF-7 breast cancer cells
while inhibiting their growth (Kang et al., 2010; Deeb et al., 2007). While the exact
mechanisms behind the antineoplastic effects of vitamin D and DHA are still under
investigation, the results of numerous research studies show that both compounds have
valuable clinical potential. Many studies have shown that the combination approach to
cancer treatment is more effective than any one compound administered alone. Although
many studies have been done in vitro to examine the individual effects of vitamin D and
DHA on cancer cells, few have studied their combined therapeutic outcome.
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Treatment for breast cancer typically involves the combination of chemotherapy
drugs which have multiple side effects and are seldom well tolerated. Therefore, any
supplemental and non-toxic treatment with the potential to increase tumor sensitivity to
anti-cancer drugs may contribute to a favorable prognosis and treatment outcome
(Bougnoux et al., 2009). Epidemiologic and experimental research suggests that the
administration of moderate doses of vitamin D (l ,25(0H)iD 3 ) in the form of calcitriol
and/or omega-3 fatty acids in the form of docosahexaenoic acid (DHA) have potential in
a clinical setting. These compounds could potentially reduce the amount of
chemotherapeutic drugs needed or decrease the length of chemotherapy treatment
required for cancer patients. The primary objective of our research was to evaluate the
efficacy of vitamin D and DHA to synergistically slow cell growth in human breast
cancer cells. Another purpose was to determine if DHA and/or vitamin D could enhance
the sensitivity of the MCF-7 cells to 5-Fluorouracil, a chemotherapy drug frequently used
in breast cancer treatment.
Materials and Methods

Cell Culture
Human mammary carcinoma cells from the MCF-7 cell line were obtained from
the American Type Institute (Rockville, MD). The MCF-7 cells were cultured in 20 ml of
Dulbecco's Modified Eagle Media (DMEM) along with 10% fetal bovine serum (FBS)
and 1% antibiotic (50% penicillin and 50% streptomycin). They were maintained in an
incubator at 37°C with 5% C02 until confluent.
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Chemicals and Reagents
Docosahexaenoic Acid (DHA), vitamin D (Calcitriol), and 5-Fluorouracil were
obtained from Fisher Scientific (Pittsburgh, PA). These compounds were dissolved in
ethanol and the stock solutions were stored in the dark at -l 8°C. Both DHA and
l,25(0H)2D 3 were further diluted with Dulbecco's Modified Eagle Media (DMEM) with
10% FBS and 1% antibiotic prior to treatment. 5- Fluorouracil was dissolved in ethanol
just prior to treatment.

Treatments
A total of six trials were conducted beginning on confluent cells. Once the cells
reached confluency, they were counted using trypan blue and a hemacytometer and
divided into two 96-well plates at a concentration of 5,000 cells per well. Cells were
incubated and allowed to adhere for 24 hours. After 24 hours, media was removed and
replaced with fresh media. Treatments were then applied to the two plates with 5,000
cells per well, and they were incubated for 72 hours (see Table 1).
Table 1 : Treatments

1

0.1% EtOH (control)

2

1 µM Calcitriol

3

25 µMDHA

4

1 µM Calcitriol + 25 µM DHA

5

15 µM 5-Fluorouracil

6

1 µM Calcitriol + 15 µM 5-Fluorouracil

7

25 µM DHA + 15 µM 5-Fluorouracil

8

1 µM Calcitriol + 25 µM DHA + 15 µM 5-Fluorouracil
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Cell Viability Assay
After the 72-hour incubation period, the cells were treated with a tetrazolium salt
solution and measured for viability using a quantitative colorimetric assay and read on a
BioTek Synergy 2 microplate reader (Winooski, VT) at 490 nm.

Statistical Analysis
Statistical analysis was carried out using SPSS version 18.0 (Chicago, IL). A oneway analysis of variance (ANOV A) was used to identify statistical significance between
treatment groups as compared to control values (p

~

0.05). A Bonferroni post hoc was

applied to further evaluate the significant differences between treatment groups.
Results
The chemotherapeutic effects of DHA, calcitriol, and 5-Fluorouracil, alone and in
various combinations, were assessed with the use of a cell viability assay following a 72hour treatment period. Results indicate that all but two treatments significantly decreased
cell viability compared to the control (p < 0.05). Treatment with calcitriol alone and in
combination with 5-Fluorouracil did not significantly alter cell viability (Fig. 1 and 2).
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Cell viability as compared to EtOH control
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Figure 1. Cell viability as compared to EtOH
are represented as mean absorbance
percentages and represent the results of six trials. Bars with an asterisk are significantly different from the
control (p < 0.05).
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Figure 2. Mean light absorbance at 490 nm for three trials (six plates total). Cell viability was evaluated
using a CCK-8 assay after a 72 hour treatment period. Higher absorbance values represent greater cell
viability.
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DHA
Consistent with the literature, treatment ofMCF-7 cells with 25 µM DHA alone
decreased cell viability by ~57% (p < 0.05). When combined with 1,25(0H)2 D3 and 5Fluorouracil, a significant reduction in cell viability occurred after 72 hours (p < 0.05).
DHA was as effective alone as it was when combined with other compounds. However,
although not statistically significant (p = 1.00), vitamin D and DHA appeared to decrease
cell viability slightly more than when either compound was administered alone,
suggesting a possible synergistic effect. Interestingly, there was no significant difference
between DHA and 5-Fluorouracil (p = 1.00), revealing that DHA was just as effective as
5-Fluorouracil in reducing cell growth.
Vitamin D
Treatment ofMCF-7s with 1µM1,25(0H)iD 3 for 72 hours did not reveal a
significant reduction in cell viability (p

=

1.00). Although not statistically significant,

cells treated with vitamin D alone actually had an increased viability as compared to the
control. Overall, vitamin D displayed an 11.5% increase in cell density as compared to
the control. These observations are unusual and inconsistent with similar research studies.
When compared to cells treated with 5-Fluorouracil alone, those treated with the
combination of 5-Fluorouracil and vitamin D displayed a significant increase in cell
viability (p < 0.05). This indicates that the growth-inhibitory effects of 5-Fluorouracil
were not sufficient to reduce the apparent increase in cell viability induced by
l ,25(0H)iD 3 .
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5-Fluorouracil
At a concentration of 15 µM, 5-Fluorouracil significantly reduced cell density of
MCF-7s after 72 hours of treatment (p < 0.05). Overall, 5-FU slowed cell growth by
~55%

which is comparable to the growth inhibitory effects of DHA. 5-Fluorouracil did

not appear to be any more effective when paired with vitamin D and/or DHA.
Discussion
The purpose of this study was to evaluate the chemotherapeutic effects of vitamin
D (l ,25(0H) 2 D 3 ) and docosahexaenoic acid (DHA) on breast cancer cells both
individually and in combination. We also sought to determine whether these compounds
would increase sensitivity to the chemotherapeutic drug 5-Fluorouracil in the MCF-7 cell
line. Our findings support the notion that DHA slows breast cancer cell growth both
alone and in combination with vitamin D and 5-Fluorouracil. Interestingly, DHA is just
as effective as 5-Fluorouracil in slowing cancer progression. In contrast to other research
findings, 1,25(0H)2 D3 did not alter cell viability when administered alone.
The effects of DHA may be mediated by a number of different cellular
mechanisms, many of which are not yet fully understood. Omega-3 fatty acids can inhibit
the proliferation of MCF-7 cells and promote apoptosis and differentiation. In addition,
DHA may suppress neoplastic formation and decrease angiogenesis in animal models
(Connolly et al., 1999). These actions may be due in part to the ability of omega-3 fatty
acids to interfere with the production of ecoisanoids from omega-6 fatty acids. In
particular, n-3 FAs inhibit the production of prostaglandin E 2 (PGE 2 ), an inflammatory
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eicosanoid derived from arachidonic acid (AA) that increases estrogen production and
has been shown to promote breast cancer cell growth. In addition to producing PGE2 , AA
also promotes the growth of tumor cells by stimulating mitosis through the activation of
protein kinase C, which is inhibited by DHA and EPA (Rose & Connolly, 1990).
To further elucidate the strong anticancer nature ofDHA in the MCF-7 cell line,
researchers evaluated the induction of oxidative stress and apoptosis as mediators of cell
death. They observed that the removal of caspase 8 in these cells completely abolished
DHA-induced cell death. Without the accumulation of reactive oxygen species (ROS),
MCF-7 cells were protected from apoptosis. This suggests that caspase 8-mediated
apoptosis is the primary form of cell death induced by DHA, and it is mediated by the
accumulation of ROS (Kang et al., 2010).
Although the amount of DHA used in this study exceeds normal physiological
levels, these findings support the notion that the protective nature of DHA may be of
value for the prevention and treatment of breast cancer. DHA may be of additional
benefit in reducing the risk of cachexia, a common side effect of cancer treatment that
occurs as a result of changes in energy expenditure. This wasting away of lean muscle
mass is not easily corrected by increasing caloric intake alone (Moses et al., 2004).
Reversal of cachexia and weight stabilization has been observed with the administration
of dietary EPA and DHA in cancer patients (Moses et al., 2004; Fearon et al., 2003),
suggesting another therapeutic use for n-3 fatty acids.
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Although we did not observe 1,25(0H)2D 3 exhibiting anticancer effects when
administered alone, a possible synergism may exist between 1,25(0H)2D3 and DHA.
Studies have indicated that the chemotherapeutic effects of DHA on cancer cells are
suppressed when combined with antioxidants and enhanced when combined with
prooxidants (Gonzalez et al., 1991). Treating MCF-7 cells with the antioxidant atocopherol was effective in protecting them from DHA-induced cell death (Kang et al.,
2010). Researchers also determined that 1,25(0H)2D3 acts as a prooxidant in cancer cells
which may explain our observation of a greater reduction in viability when cells were
treated with 1,25(0H)2D 3 and DHA in combination (Koren et al., 2001 ). Further research
should be conducted to evaluate the combined effects of DHA and prooxidants such as
1,25(0H)2D3.
Rather than causing a reduction in cell viability, results from this study revealed
that a single treatment of 1,25(0H)2D 3 tended to increase cell viability. One possible
explanation for this is that the timecourse was inadequate to facilitate the slower kinetics
of 1,25(0H)2 D3 in vitro. Previous studies have observed that apoptosis in MCF-7 cells
first occurs after the third day of treatment with 1,25(0H)2D3 due to intracellular
transformations that must occur first (James et al., 1996). In addition, several studies
grew MCF-7 cells in medium containing 1,25(0H)2D 3 prior to the incubation period
(Narvaez & Welsh 2001; Wang et al., 2000). Thus, pretreatment with vitamin D may be
necessary for the cells to become susceptible to the antiproliferative effects.
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Breast cancer cells use multiple mechanisms to evade 1,25(0H) 2 Drmediated
growth inhibition (Welsh, 2007) and several factors may have contributed to our
observations. Vitamin D-mediated apoptosis in MCF-7 cells may be inhibited by the
overexpression of the antiapoptotic protein Bcl-2 which is downregulated in response to
1,25(0HhD 3 . Researchers evaluated the effects of 1,25(0H)2 D 3 on MCF-7 cells
overexpressing Bcl-2 and found that the cells were entirely protected from vitamin Dmediated apoptosis (Mathiasen et al., 1999). The loss of VDR expression and/or changes
in receptor co-regulators could also result in 1,25(0H)2 D 3 resistance (Welsh, 2007).
Additionally, the expression of some oncogenes can potentially inhibit the
anti proliferative effects of vitamin D (Agadir et al., 1999).
It is well documented that both vitamin D and DHA have potential as anticancer

agents in animal and cell culture models, but their clinical potential is still under
investigation. Most studies first observe the antineoplastic effects of vitamin D with
doses of 1 nm in vitro, a concentration that can be achieved in a clinical setting with
intermittent oral dosing (Beer & Myrthue, 2004). Potential for the clinical application of
DHA is also very promising. Bums et al. found that the maximum non-toxic dose of
omega-3 fatty acids administered in a clinical setting was 0.3 g/kg per day or up to 21
g/day for a 70 kg patient. Results from similar studies have indicated that only small
amounts of n-3 fatty acids are needed to significantly influence cytokine production
(Hardman, 2004).
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In conclusion, our research supports a protective role of DHA on breast cancer
progression, one that is comparable to that of 5-Fluorouracil. It has been well established
that vitamin D has similar effects. In addition to their possible chemopreventive role,
both compounds could potentially enhance the therapeutic effects of traditional breast
cancer treatments in a clinical setting. Our data indicates the possibility of a synergism
between DHA and 1,25(0H)2 D 3 , yet additional studies are warranted to further evaluate
this effect. In addition, clinical trials are necessary to evaluate the safety and efficacy of
high intermittent dosing of these compounds as they apply to patient therapy.

REFERENCES
Abbas S, Linseisen J, Slanger T, Kropp S, Mutschelknauss EJ, Flesch-Janys D, ChangClaude J. Serum 25-hydroxyvitamin D and risk of post-menopausal breast cancer
- results of a large case-control study. Carcinogenesis. 2008; 29:93-99.
Agadir A, Lazzaro G, Zheng Y, Zhang XK, Mehta R. Resistance of HBLlOO human
breast epithelial cells to vitamin D action. Carcinogenesis. 1999; 20: 577-582.
American Institute for Cancer Research/World Cancer Research Fund. Food, Nutrition
and the Prevention of Cancer: A Global Perspective (American Institute for
Cancer Research, Washington, 1997).
Beer TM, Myrthue A. Calcitriol in cancer treatment: from the lab to the clinic. Molecular
Cancer Therapies. 2004; 3(3):373-381.
Burns CP, Halabi S, Clamon GH, Hars V, Wagner BA, Hohl RJ, Lester E, Kirshner JJ,
Vinciguerra V, Paskett E. Phase I clinical study of fish oil fatty acid capsules for
patients with cancer cachexia: cancer and leukemia group B study 9473. Clinical
Cancer Research. 1999; 5: 3942.
Chlebowski RT, Johnson KC, Kooperberg C, et al. Calcium plus vitamin D
supplementation and the risk of breast cancer. Journal of the National Cancer
Institute. 2008; 100:1581-1591.
Connolly JM, Gilhooly EM, Rose DP. Effects of reduced dietary linoleic acid intake,
alone or combined with an algal source of docosahexaenoic acid, on MDA-MB231 breast cancer cell growth and apoptosis in nude mice. Nutrition and Cancer.
1999; 35(1):44-49.
Crew KD, Gammon MD, Steck SE, et al. Association between plasma 25hydroxyvitamin D and breast cancer risk. Cancer Prevention Research. 2009;
2:598-604.
Deeb KK, Trump DL, Johnson CS. Vitamin D signaling pathways in cancer: potential for
anticancer therapeutics. Nature Reviews. 2007; 7:684-700.
Fay MP, Freedman LS, Clifford CK, Midthune DN. Effect of different types and amounts
of fat on the development of mammary tumors in rodents: a review. Cancer
Research. 1997; 57:3979-3988.

39

Fearon KCH, von Meyenfeldt MF, Moses AG, van Geenen R, Roy A, Gouma DJ,
Giacosa A, Van Gossum A, Bauer J, Barber MD, Aaronson NK, Voss AC,
Tisdale MJ. Effect of a protein and energy dense n-3 fatty acid enriched oral
supplement on loss of weight an lean tissue in cancer cachexia: a randomized
double blind trial. GUT 2003; 52(10):1479-1486.
Freedman DM, Chang SC, Falk RT, et al. Serum levels of vitamin D metabolites and
breast cancer risk in the prostate, lung, colorectal, and ovarian cancer screening
trial. Cancer Epidemiology, Biomarkers & Prevention. 2008; 17:889-894.
Go VLW, Wong DA, Butrum R. Diet, nutrition and cancer prevention: where are we
going from here? Journal of Nutrition. 2001; 131 :3121 S-3126S.
Gonzalez MJ, Schemmel RA, Gray JI, Dugan L Jr, Sheffield LG, Welsch CW. Effect of
dietary fat on growth ofMCF-7 and MDA-MB231 human breast carcinomas in
athymic nude mice: relationship between carcinoma growth and lipid
peroxidation product levels. Carcinogenesis. 1991; 12: 1231-123 5.
Grammatikos SI, Subbaiah PV, Victor TA, Miller WM. n-3 and n-6 fatty acid processing
and growth effects in neoplastic and non-cancerous human mammary epithelial
cells. British Journal of Cancer. 1994; 70:219-227.
Hardman WE. Omega-3 fatty acids to augment cancer therapy. Journal of Nutrition.
2002: 132:3508S-3512S.
James SY, Mackay AG, Colston KW. Effects of 1,25 dihydroxyvitamin D 3 and its
analogues on induction of apoptosis in breast cancer cells. The Journal of Steroid
Biochemestry and Molecular Biology. 1996; 58:395-401.
Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics, 2010. Cancer Journal for Clinicians.
2010; 60:277-300.
Kang KS, Wang P, Yamabe N, Fukui M, Jay T, Zhu BT. Docosahexaenoic acid induces
apoptosis in MCF-7 cells in vitro and in vivo via reactive oxygen species
formation and caspase 8 activation. Plos One. 201 O; 5(4):e10296.
Koren R, Hadari-Naor I, Zuck E, Rotem C, Liberman UA, Ravid A. Vitamin Dis a
prooxidant in breast cancer cells. Cancer Research. 2001; 61: 1439-1444.
Lim HS, Roychoudhuri R, Peto J, Schwartz G, Baade P, Moller H. Cancer survival is
dependent on season of diagnosis and sunlight exposure. International Journal of
Cancer. 2006; 119:1530-1536.

40

Ma Y, Trump DL, Johnson CS. Vitamin Din combination cancer treatment. Journal of
Cancer. 2010; 1:101-107.
McCullough ML, Stevens VL, Patel R, Jacobs EJ, et al. Serum 25-hydroxyvitamin D
concentrations and postmenopausal breast cancer risk: a nested case control study
in the cancer prevention study-II nutrition cohort. Breast Cancer Research. 2009;
11 :R64.
Melamed ML, Michos ED, Post M, Astor B. 25-hydroxyl vitamin D levels and the risk of
mortality in the general population. Archives of Internal Medicine. 2008; 168(15):
1629-1637.
Moses AWG, Slater C, Preston T, Barber MD, Fearon KCH. Reduced total energy
expenditure and physical activity in cachectic patients with pancreatic cancer can
be modulated by an energy and protein dense oral supplement enriched with n-3
fatty acids. British Journal of Cancer. 2004; 90(5): 996-1002.
Narvaez CJ, Welsh J. Role of mitochondria and caspases in vitamin D-mediated
apoptosis of MCF-7 breast cancer cells. Journal of Biological Chemistry. 2001;
276(12): 9101-9107.
Nelms M, Sucher K, Long S. Nutrition Therapy and Pathophysiology. Belmont, CA:
Thompson Brooks/Cole, 2007.
Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer Journal
for Clinicians. 2005; 55:74-108.
Peto J. Cancer epidemiology in the last century and the next decade. Nature. 2001;
411:390-395.
Rejnmark L, Tietze A, Vestergaard P, et al. Reduced prediagnostic 25-hydroxyvitamin D
levels in women with breast cancer: a nested case-control study. Cancer
Epidemiology, Biomarkers & Prevention. 2009; 18:2655-2660.
Robsahm TE, Tretli S, Dahlback A, Moan J. Vitamin D 3 from sunlight may improve the
prognosis of breast-, colon- and prostate cancer (Norway). Cancer Causes and
Control. 2004; 15:149-158.
Wang Q, Yang W, Uytingco MS, Christakos S, Wieder R. 1,25-dihydroxyvitamin D3 and
all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell
death. Cancer Research. 2000; 60:2040-2048.
Welsh J. Targets of vitamin D receptor signaling in the mammary gland. Journal of Bone
and Mineral Research. 2007; 22:V86-V90.
41

